 |
Recombinant human C1 inhibitor |
|---|---|
| Trade Name | |
| Orphan Indication | Prevention and/or treatment of delayed graft function after solid organ transplantation |
| USA Market Approval | USA |
| USA Designation Date | 2006-06-09 00:00:00 |
| Sponsor | Pharming Group N.V.;P. O. Box 451 Darwinweg 24, 2300 Al Leiden;Leiden |
